Literature DB >> 24794112

Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu(2)/mGlu(3) NAMs.

Cody J Wenthur1, Ryan D Morrison1, J Scott Daniels1, P Jeffrey Conn1, Craig W Lindsley2.   

Abstract

Herein we report the design and synthesis of a series of substituted pyrazolo[1,5-a]quinazolin-5(4H)-ones as negative allosteric modulators of metabotropic glutamate receptors 2 and 3 (mGlu2 and mGlu3, respectively). Development of this series was initiated by reports that pyrazolo[1,5-a]quinazoline-derived scaffolds can yield compounds with activity at group II mGlu receptors which are prone to molecular switching following small structural changes. Several potent analogues, including 4-methyl-2-phenyl-8-(pyrimidin-5-yl)pyrazolo[1,5-a]quinazolin-5(4H)-one (10b), were discovered with potent in vitro activity as dual mGlu2/mGlu3 NAMs, with excellent selectivity versus the other mGluRs.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 3; Negative allosteric modulator (NAM); mGlu(2) receptor; mGlu(3) receptor

Mesh:

Substances:

Year:  2014        PMID: 24794112      PMCID: PMC4075068          DOI: 10.1016/j.bmcl.2014.04.051

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  25 in total

1.  The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Authors:  Corrado Corti; Giuseppe Battaglia; Gemma Molinaro; Barbara Riozzi; Anna Pittaluga; Mauro Corsi; Manolo Mugnaini; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 2.  The involvement of glutamate in the pathophysiology of depression.

Authors:  A Palucha; A Pilc
Journal:  Drug News Perspect       Date:  2005-05

3.  Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?

Authors:  F Matrisciano; I Panaccione; M Zusso; P Giusti; R Tatarelli; L Iacovelli; A A Mathé; S H M Gruber; F Nicoletti; P Girardi
Journal:  Mol Psychiatry       Date:  2007-08       Impact factor: 15.992

Review 4.  The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia.

Authors:  P J Harrison; L Lyon; L J Sartorius; P W J Burnet; T A Lane
Journal:  J Psychopharmacol       Date:  2008-05       Impact factor: 4.153

5.  Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.

Authors:  Sameer Sharma; Alice L Rodriguez; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-05-29       Impact factor: 2.823

Review 6.  Pharmacology and functions of metabotropic glutamate receptors.

Authors:  P J Conn; J P Pin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

7.  Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus.

Authors:  Anni-Maija Linden; Melvin Baez; Marcelle Bergeron; Darryle D Schoepp
Journal:  Neuropharmacology       Date:  2006-06-02       Impact factor: 5.250

8.  Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.

Authors:  J A Monn; M J Valli; S M Massey; M M Hansen; T J Kress; J P Wepsiec; A R Harkness; J L Grutsch; R A Wright; B G Johnson; S L Andis; A Kingston; R Tomlinson; R Lewis; K R Griffey; J P Tizzano; D D Schoepp
Journal:  J Med Chem       Date:  1999-03-25       Impact factor: 7.446

Review 9.  The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?

Authors:  Nikolaos Pitsikas
Journal:  Eur J Pharmacol       Date:  2013-12-18       Impact factor: 4.432

Review 10.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

View more
  3 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

Review 3.  Recent advances in the medicinal chemistry of group II and group III mGlu receptors.

Authors:  Chaobin Jin; Shutao Ma
Journal:  Medchemcomm       Date:  2017-01-13       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.